$66.26
0.44% yesterday
Nasdaq, Dec 12, 10:11 pm CET
ISIN
US09061G1013
Symbol
BMRN

Biomarin Pharmaceutical Stock price

$66.26
+0.13 0.20% 1M
-18.29 21.63% 6M
-30.16 31.28% YTD
-29.64 30.91% 1Y
-17.53 20.92% 3Y
-14.64 18.10% 5Y
-25.26 27.60% 10Y
Nasdaq, Closing price Thu, Dec 12 2024
+0.29 0.44%
ISIN
US09061G1013
Symbol
BMRN
Sector
Industry

Key metrics

Market capitalization $12.63b
Enterprise Value $12.31b
P/E (TTM) P/E ratio 39.90
EV/FCF (TTM) EV/FCF 38.48
EV/Sales (TTM) EV/Sales 4.48
P/S ratio (TTM) P/S ratio 4.60
P/B ratio (TTM) P/B ratio 2.33
Revenue growth (TTM) Revenue growth 19.99%
Revenue (TTM) Revenue $2.75b
EBIT (operating result TTM) EBIT $390.76m
Free Cash Flow (TTM) Free Cash Flow $319.89m
Cash position $930.44m
EPS (TTM) EPS $1.66
P/E forward 29.48
P/S forward 4.48
EV/Sales forward 4.37
Short interest 3.04%
Show more

Is Biomarin Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,889 stocks worldwide.

Biomarin Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Biomarin Pharmaceutical forecast:

23x Buy
77%
7x Hold
23%

Analyst Opinions

30 Analysts have issued a Biomarin Pharmaceutical forecast:

Buy
77%
Hold
23%

Financial data from Biomarin Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,747 2,747
20% 20%
100%
- Direct Costs 628 628
10% 10%
23%
2,118 2,118
23% 23%
77%
- Selling and Administrative Expenses 848 848
7% 7%
31%
- Research and Development Expense 780 780
9% 9%
28%
490 490
128% 128%
18%
- Depreciation and Amortization 100 100
2% 2%
4%
EBIT (Operating Income) EBIT 391 391
246% 246%
14%
Net Profit 322 322
119% 119%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Biomarin Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomarin Pharmaceutical Stock News

Negative
MarketBeat
21 days ago
BioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%.
Neutral
Seeking Alpha
21 days ago
Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acondrophasia, hemophilia and patent expiry issues, making the medium term outlook tricky. Long term, a new management is promising $4bn of revenues by 2027, and long term mid-teen revenue growth.
Neutral
PRNewsWire
27 days ago
SAN RAFAEL, Calif. , Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia.
More Biomarin Pharmaceutical News

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Head office United States
CEO Alexander Hardy
Employees 3,401
Founded 1997
Website www.biomarin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today